Search / Trial NCT06613256

Characterisation of Endothelial Cells in Different Inflammatory Pathologies

Launched by ROYAL SURREY COUNTY HOSPITAL NHS FOUNDATION TRUST · Sep 23, 2024

Trial Information

Current as of December 21, 2024

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking to understand how certain cells in our blood vessels, called endothelial cells, change when patients are experiencing serious conditions like sepsis (a severe infection) or after major surgery. The main goal is to identify different molecular pathways, which are like communication signals within our cells, that become more active or less active during these inflammatory conditions. By studying these changes, researchers hope to gain insights that could improve treatment options for patients dealing with these health issues.

To participate in this study, individuals must be at least 18 years old and fall into specific groups: healthy volunteers, patients undergoing planned major surgery, or critically ill patients who have been admitted to the intensive care unit with sepsis. Participants can expect to provide consent and undergo some tests related to their condition. It’s important to note that certain individuals, such as those with specific inflammatory diseases or recent major trauma, may not be eligible to participate. This research is still in the recruiting phase, meaning they are actively looking for volunteers to join the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Healthy volunteer
  • Adult ≥ 18 years
  • Able and willing to give consent
  • Surgical patients
  • Adult ≥ 18 years
  • Patients admitted to RSFT for planned major surgery
  • Critically ill patients
  • Adult ≥ 18 years
  • Emergency admission to ICU at RSFT
  • Meets the sepsis 3.0 definition
  • Exclusion Criteria:
  • Healthy volunteer
  • Not currently a patient within the hospital
  • Absence of inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes, cardiovascular disease and CKD.
  • Not on immunomodulatory medications, such as corticosteroids
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)
  • Surgical patients
  • Patients with restricted liberty, prisoners or under legal protection
  • Anticipated prohibitively difficult venous cannulation
  • Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, sepsis, diabetes with end organ damage, cardiovascular disease and CKD
  • Currently prescribed immunomodulatory medication or immunocompromised
  • Received chemotherapy within 2 weeks of predicted sampling
  • Receiving vasopressor support prior to surgery
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)
  • Critically ill patients
  • Patients with restricted liberty, prisoners or under legal protection• Anticipated prohibitively difficult venous cannulation
  • Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes with end organ damage, cardiovascular disease and CKD.
  • Currently prescribed immunomodulatory medication or immunocompromised
  • Received chemotherapy within 2 weeks of predicted sampling.
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)

About Royal Surrey County Hospital Nhs Foundation Trust

Royal Surrey County Hospital NHS Foundation Trust is a leading healthcare institution dedicated to providing high-quality clinical care and advancing medical research. As a prominent sponsor of clinical trials, the Trust is committed to enhancing patient outcomes through innovative research initiatives and collaboration with academic and industry partners. With a focus on patient safety and ethical standards, Royal Surrey County Hospital NHS Foundation Trust aims to contribute to the development of new therapies and treatment protocols, ultimately improving health care delivery in the community and beyond.

Locations

Guildford, Surrey, United Kingdom

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0